Clinical Trial

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Protocol Amendment History 1 change
notable Trial sites expanded: 2 -> 5 locations 2026-06-24
Trial Details
NCT Number NCT07241546
Lead Sponsor Arrowhead Pharmaceuticals
Conditions Asthma
Enrollment 36 participants
Start Date 2026-03-30
Primary Completion 2027-12 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-23